BeiGene Ltd. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (21)

Latest Posts

About This Stock More About This Stock
Week In Review: China Life Science Announces $5 Billion In Deals, A Weekly Record
Article By: ChinaBio® Today
Saturday, July 18, 2020 5:38 PM EDT
BeiGene, a Beijing oncology drug biopharma, announced a $2.1 billion private placement that will bring its cash holdings to almost $5.5 billion The company is developing a portfolio of 25 candidates, with several of them in Phase III tests.
In this article: AMGN, BGNE, BNTX
Read
Week In Review: Leo Pharma Acquires Atopic Dermatitis Candidate From Taiwan-China Company In $570 Million Deal
Article By: ChinaBio® Today
Saturday, April 18, 2020 4:41 PM EDT
Leo Pharma, a Denmark dermatology company, acquired global rights to a novel treatment for atopic dermatitis (AD) and allergic asthma in an agreement worth up to $570 million. Leo acquired FB825 from Oneness Biotech of Taiwan and Microbio Shanghai.
In this article: SVA, BGNE
Read
Week In Review: CICC Capital Closes $229 Million China Fund For Biologics
Article By: ChinaBio® Today
Saturday, February 29, 2020 1:50 PM EDT
CICC Capital closed a $229 million investment fund for biologics, with investments coming mainly from Chinese organizations inside and outside the biopharma industry. Some of the money will go to companies making COVID-19 vaccines and therapies.
In this article: AZN, GSK, PFE, GILD, MRNA, BGNE, VIR
Read
Week In Review: Shanghai's I-Mab Plans $100 Million NASDAQ IPO On January 16
Article By: ChinaBio® Today
Sunday, January 5, 2020 10:20 AM EDT
I-Mab, a Phase III Shanghai immunoncology-autoimmune biopharma, announced the terms for its $100 million IPO on the NASDAQ exchange at a market value of $750 million. The company plans to offer 7.4 million shares between $12 and $15.
In this article: BGNE, LPTX
Read
Week In Review: Ally Bridge Leads $140 Million Of Investments In Three Medical Device Companies
Article By: ChinaBio® Today
Saturday, December 21, 2019 5:09 PM EDT
Ally Bridge Group, a Hong Kong-New York life science investment firm, announced it has led $140 million of investments in three new medical device companies, bringing its 18-month total to more than $500 million in private life science companies.
In this article: BGNE, TCON
Read

PARTNER HEADLINES

Latest Tweets for $BGNE

No tweets yet!